- Home
- EBS vs NPCE Comparison
EBS vs NPCE Comparison
Compare EBS & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- NPCE
- Stock Information
- Founded
- EBS 1998
- NPCE 1997
- Country
- EBS United States
- NPCE United States
- Employees
- EBS N/A
- NPCE N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- NPCE Medical Specialities
- Sector
- EBS Health Care
- NPCE Health Care
- Exchange
- EBS Nasdaq
- NPCE Nasdaq
- Market Cap
- EBS 393.9M
- NPCE 358.3M
- IPO Year
- EBS 2006
- NPCE 2021
- Fundamental
- Price
- EBS $5.88
- NPCE $12.95
- Analyst Decision
- EBS Strong Buy
- NPCE Buy
- Analyst Count
- EBS 3
- NPCE 6
- Target Price
- EBS $14.33
- NPCE $14.83
- AVG Volume (30 Days)
- EBS 1.2M
- NPCE 138.5K
- Earning Date
- EBS 05-07-2025
- NPCE 05-13-2025
- Dividend Yield
- EBS N/A
- NPCE N/A
- EPS Growth
- EBS N/A
- NPCE N/A
- EPS
- EBS N/A
- NPCE N/A
- Revenue
- EBS $965,400,000.00
- NPCE $79,906,000.00
- Revenue This Year
- EBS N/A
- NPCE $19.53
- Revenue Next Year
- EBS $19.88
- NPCE $11.83
- P/E Ratio
- EBS N/A
- NPCE N/A
- Revenue Growth
- EBS N/A
- NPCE 22.14
- 52 Week Low
- EBS $4.02
- NPCE $5.45
- 52 Week High
- EBS $15.10
- NPCE $15.11
- Technical
- Relative Strength Index (RSI)
- EBS 57.55
- NPCE 60.82
- Support Level
- EBS $4.71
- NPCE $11.19
- Resistance Level
- EBS $6.70
- NPCE $12.49
- Average True Range (ATR)
- EBS 0.43
- NPCE 0.67
- MACD
- EBS 0.14
- NPCE 0.22
- Stochastic Oscillator
- EBS 58.79
- NPCE 75.74
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.